SCHEMBL26447886

SCHEMBL26447886

CC(C)(C)OC(=O)N1CCN(c2ccc(Nc3ncc(F)c(-c4ccc5ncsc5c4)n3)nc2)CC1

nearest known ligand 0.81

Predicted protein targets (top 3)

geneUniProtsupporting neighboursconfidence
▸ DYRK2 Q92630 19/20 0.81
▸ PIM1 P11309 1/20 0.53
▸ CDK6 Q00534 1/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30569706 1.00 DYRK2 (0.81) DYRK2PIM1CDK6
SCHEMBL30569697 0.90 DYRK2 (1.00) DYRK2
SCHEMBL26447880 0.90 DYRK2 (1.00) DYRK2
SCHEMBL26447870 0.88 DYRK2 (0.79) DYRK2CDK6
SCHEMBL30679280 0.88 DYRK2 (0.79) DYRK2CDK6
SCHEMBL30569698 0.87 DYRK2 (0.73) DYRK2PIM1CDK6
SCHEMBL26447967 0.87 DYRK2 (0.73) DYRK2PIM1CDK6
SCHEMBL24483228 0.86 DYRK2 (0.60) DYRK2PIM1CDK6
SCHEMBL29684290 0.86 DYRK2 (0.60) DYRK2PIM1CDK6
SCHEMBL30569700 0.85 DYRK2 (0.83) DYRK2PIM1CDK6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4282864-B1 CDK6/DYRK2 DUAL-TARGET INHIBITOR, AND PREPARATION METHOD THEREFOR AND USE THEREOF JIANGSU TASLY DIYI PHARMACEUTICAL CO LTD (CN) 2025-08-13 — — EP disclosed
EP-4282864-A1 CDK6/DYRK2 DUAL-TARGET INHIBITOR, AND PREPARATION METHOD THEREFOR AND USE THEREOF Jiangsu Tasly Diyi Pharmaceutical Co., Ltd. (CN) 2023-11-29 — — EP disclosed
EP-4282864-A1 CDK6/DYRK2 DUAL-TARGET INHIBITOR, AND PREPARATION METHOD THEREFOR AND USE THEREOF Jiangsu Tasly Diyi Pharmaceutical Co., Ltd. (CN) 2023-11-29 — — EP disclosed
US-20230303553-A1 CDK6/DYRK2 DUAL-TARGET INHIBITOR, AND PREPARATION METHOD THEREFOR AND USE THEREOF JIANGSU TASLY DIYI PHARMACEUTICAL CO., LTD. (CN) 2023-09-28 — — US disclosed
CN-113149978-A Intermediate compound, preparation method and application thereof 中国药科大学 2021-07-23 — — CN disclosed
CN-112390793-B CDK6/DYRK2 double-target inhibitor and preparation method and application thereof 中国药科大学 2021-04-27 — — CN disclosed
CN-112390793-A CDK6/DYRK2 double-target inhibitor and preparation method and application thereof 中国药科大学 2021-02-23 — — CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230303553-A1 CDK6/DYRK2 DUAL-TARGET INHIBITOR, AND PREPARATION METHOD THEREFOR AND USE THEREOF CDK6, DYRK2, CDK16 DYRK2 2/4885PIM1 393/4885CDK6 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback